Ovarian cancer stages I and II: predictions and 5-year survival in two decades.
Today, when all studies of treatment of ovarian cancer stages III and IV show disappointing long-term survival despite extensive surgery and chemotherapy, it is of interest to look a little further at the characteristics of early ovarian cancer to help the development of screening methods. For this purpose, stages I and II were analyzed during the periods 1969 to 1972 (group A, n = 172) and 1979 to 1982 (group B, n = 179). The total survival for stages I and II was 57% in group A and 66% in group B. In group A, survival was 74% for stage I and 41% for stage II; the corresponding data for group B were 68 and 65%. The difference between groups A and B for stage II is statistically significant. In stage I, survival was not found to be dependent on hysterectomy and bilateral salpingo-oophorectomy (SOEBH) or bilateral/unilateral salpingo-oophorectomy (SOEB/SOEU). In stage II, however, survival increased significantly after SOEBH. The best survival (80%, 28/35) occurred in group B, stage II, where high-voltage treatment was followed by melphalan for 6 months postoperatively.
Granberg
S
S
Department of Oncology, University of Göteborg, Sahlgrenska sjukhuset, Sweden.
Norén
H
H
Friberg
L G
LG
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007044:Hysterectomy; D015994:Incidence; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D010052:Ovariectomy; D011379:Prognosis; D013548:Sweden; D013997:Time Factors